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cyclic ß-hairpin peptide containing two sulfated tyrosine residues at positons i and i+2 along one ß-strand.
The entry of human immunodeficiency virus type-1 (HIV-1) into cells requires an association of the viral envelope glycoprotein gp120 first with the cellular receptor CD4 and 15 then with one of the co-receptors, most commonly CCR5. Major conformational changes occur in gp120 after docking to CD4 1 , commonly referred to as the CD4-induced (CD4i) state, which lead to the assembly of a highly conserved binding pocket for the N-terminus of CCR5. The high affinity 20 interaction of the N-terminus of CCR5 with the gp120-CD4 complex requires the unusual post-translational O-sulfation of several tyrosine residues, in particular, at positions 10 and 14 in CCR5. 2, 3 Interestingly, several human antibodies directed against this site in gp120, including the monoclonal antibody 25 (mAb) 412d, are also tyrosine-sulfated (Tys) in their antigen binding sites. 4 Recent NMR and crystallographic studies of structures formed by complexation of mAb 412d, or a CCR5-derived peptide, with gp120 and CD4, 5 revealed that the tyrosine- are linear CCR5-derived peptides, the mAbs 48d and 17b, and nucleic acid ligands (aptamers). [6] [7] [8] [9] The design of cyclic peptidomimetics constrained into a ß-hairpin conformation represent one possible approach to mimic α-helical epitopes, [10] [11] [12] In this case, molecular models To test this hypothesis, the target mimetic 1 was synthesized and its structure in aqueous solution was 60 investigated by 1 H-NMR spectroscopy. The NMR data provide strong support for a stable ß-hairpin backbone conformation in this cyclic peptide in aqueous solution. The appearance of a network of cross-strand NOEs, 3 J(Hα,NH) coupling constants of >8 Hz for residues in the ß-strands, and 65 slow NH exchange rates for peptide NH groups predicted to form cross-strand H-bonds, are all consistent with a stable ß-hairpin conformation. Average solution structures calculated using NOE-derived distance restraints adopt a well-defined ß-hairpin structure ( Figure 1C ) with a type-II' ß-turn formed by Figure 1D . The inhibitory activity of mimetic 1 was tested using a 75 surface plasmon resonance biosensor (BIAcore) and the mAb 17b, whose epitope directly overlaps the CCR5 binding site on CD4i gp120 5, [13] [14] [15] . In a first step, mAb 17b was coupled to a CM5 sensor chip surface, and its binding affinity to a gp120-CD4 complex was measured using recombinant gp120 from strain JR-FL pre-mixed with a five-fold excess of a tetrameric CD4 fusion protein (CD4-IgG2). 16 The dissociation 5 constant measured in this way (K d =2.5 nM) was in good agreement with data published previously. 17 Neither gp120 nor CD4-IgG2 alone showed significant affinity for the immobilized 17b mAb in this assay. Next, fixed concentrations of gp120 from strain JR-FL (50 nM) and CD4-10 IgG2 (250 nM) were preincubated with varying concentrations of mimetic 1, before elution over the immobilized 17b mAb. The dependence of the BIAcore response on mimetic 1 concentration showed a sigmoid inhibition curve with an IC 50 of 25 µM (Figure 2 ). An analogue of mimetic 1 with both Tys 15 residues replaced by Tyr (peptide 2) showed only weak inhibitory activity (IC 50 ≈ 400 µM), confirming the expected importance of the sulfo groups for binding to CD4i gp120. BIAcore was also used to show that gp120 interacts with CD4-IgG2, and that this interaction is not inhibited by 20 mimetic 1. These results show that mimetic 1 inhibits the interaction between CD4i gp120 and the mAb 17b, by blocking the CCR5 binding site. showing the decrease in response upon addition of increasing amounts of peptide 1 (0, 0.1, 1, 5, 10, 50, 100, 500 and 1000 µM) to fixed concentrations of gp120 from strain JR-FL (50 nM) and CD4-IgG2 (250 nM) before elution over the mAb 17b immobilized on a CM5 sensor chip.
Bottom, normalised response versus peptide concentration. 50 Next, we examined whether the mimetic can inhibit HIV-1 infection. For this, two Env-pseudotyped viruses with high (NAB09pre.106) 18 and comparatively low (JR-FL) sensitivity to the CCR5 inhibitors AD101 and PSC-RANTES were Depicted are the 95% confidence intervals.
a single-round infection assay using the luciferase reporter cells JC53-BL (TZM-bl). 19, 20 Interestingly, mimetic 1 exhibited inhibitory activity against the NAB9pre.106 strain.
75
However, the inhibitory activity was of moderate potency, despite the relatively high sensitivity of this strain to other CCR5 inhibitors. The more resistant strain JR-FL was not inhibited by mimetic 1 in the concentration range tested (Figure 3, top) . independently of CD4, and so rule out toxic effects on the cells by 1.
The inhibitory activity observed here supports the initial design concept for mimetic 1 and its mode of action as an antagonist of the CCR5 binding site on CD4i gp120.
